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Background: Allergy to peanuts results in severe anaphylactic responses in affected individuals, and has dramatic
effects on society and public policy. Despite the health impacts of peanut-induced anaphylaxis (PIA), relatively little
is known about immune mechanisms underlying the disease. Using a mouse model of PIA, we evaluated mice
with deletions in four distinct immune molecules (IL7Rα, L-selectin, CD34, CD103), for perturbed responses.
Methods: PIA was induced by intragastric sensitization with peanut antigen and cholera toxin adjuvant, followed
by intraperitoneal challenge with crude peanut extract (CPE). Disease outcome was assessed by monitoring body
temperature, clinical symptoms, and serum histamine levels. Resistant mice were evaluated for total and antigen
specific serum IgE, as well as susceptibility to passive systemic anaphylaxis.
Results: PIA responses were dramatically reduced in IL7Rα−/− and L-selectin−/− mice, despite normal
peanut-specific IgE production and susceptibility to passive systemic anaphylaxis. In contrast, CD34−/− and CD103−/−
mice exhibited robust PIA responses, indistinguishable from wild type controls.
Conclusions: Loss of L-selectin or IL7Rα function is sufficient to impair PIA, while CD34 or CD103 ablation has no
effect on disease severity. More broadly, our findings suggest that future food allergy interventions should focus on
disrupting sensitization to food allergens and limiting antigen-specific late-phase responses. Conversely, therapies
targeting immune cell migration following antigen challenge are unlikely to have significant benefits, particularly
considering the rapid kinetics of PIA.
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Food allergies affect a significant portion of the popula-
tion, with direct effects on health and quality of life. Of
all food sensitivities, peanut allergies account for the
most fatalities [1] and exposure to peanut antigen in
affected individuals results in severe, rapid, systemic ana-
phylactic responses. Despite the severity of peanut ana-
phylactic responses, few effective treatments or therapies
exist and most focus on limiting allergen exposure and
management of symptoms. While peanut allergy preva-
lence is relatively low (estimated ~1-2% of the total
population), the consequences of exposure are high and* Correspondence: kelly@brc.ubc.ca
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reproduction in any medium, provided the orthe effects of peanut allergy are disproportionately large
in society [2,3].
In affected individuals, peanut-specific IgE antibodies
bind to FcεR on mast cells and basophils, and are cross
linked by peanut antigens, resulting in rapid release of
immune mediators including histamine, leukotrienes,
prostaglandins and platelet-activating factor following
exposure (as reviewed in [4]). These mediators contrib-
ute to a range of pathological symptoms, including
increased vascular permeability (resulting in localized
edema, decreased blood pressure, and rapid decrease
in body temperature), diarrhea and vomiting, and fatal
respiratory failure without treatment.
To explore mechanisms underlying this pathology,
a mouse model of peanut-induced anaphylaxis (PIA)
was established, which closely approximates the clinical
symptoms and pathology observed in peanut-allergicLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ings of peanut antigen with adjuvant. Subsequent inter-
peritoneal challenge with peanut protein results in rapid
mast cell degranulation, elevated serum histamine, and
decreases in blood volume and body temperature. This
model has been utilized successfully to highlight the
role of B cells, CD40 ligand and mast cells and the
effects of therapeutic interventions (blocking histamine
and/or platelet activating factor) on peanut-induced ana-
phylactic responses [5,6]. In a related fatal PIA model,
the importance of mast cells, macrophages, IgG and IgE
have also been reported [7]. Similarly, in an adjuvant
based model of PIA, treatment by a CD4 blockade could
provide protection from disease, by increasing the fre-
quency of Treg [8]. However, no studies have focussed on
other adaptive immune molecules, including molecules
regulating immune cell migration or adhesion, in the
PIA model.
In our study, we provide the first analysis of four im-
mune molecules (IL7Rα, L-selectin, CD34, CD103) in
the PIA model, to determine the effect of altered adap-
tive responses and cell migration on food-induced ana-
phylaxis. IL7Rα (CD127) is expressed on lymphoid cells
and plays key roles in regulating lymphoid development,
survival and proliferation [9-11]. L-selectin (CD62L) is
constitutively expressed on leukocytes and involved in
neutrophil extravasation [12], lymphocyte rolling and
migration into lymph nodes [13] and pathology asso-
ciated with T cell-mediated inflammation in a number
of disease models [14,15]. CD34 is widely used as a clin-
ical marker for the enrichment of human hematopoietic
stem cells and a marker of pluripotency. However, CD34
is also expressed by a range of hematopoietic cells and
vascular endothelia and promotes optimal immune cell
migration (particularly for mast cells, eosinophils and
dendritic cells) and the maintenance of vascular integrity
[16-20]. CD103 (integrin alpha E) is expressed on sub-
sets of dendritic cells (DCs) and lymphocytes within the
gut tissues, where it acts as an E-cadherin ligand and
has been proposed as a key molecule regulating oral tol-
erance (detailed by Scott et al. [21]).
Here we have performed a survey of mice deficient in
these immunoreceptors to identify pathways that alter
susceptibility to PIA. Our findings demonstrate that ab-
lation of either IL7R or L-sel dramatically reduces the se-
verity of PIA, whereas ablation of two migration-
associated immune genes, Cd34 or Cd103, has no effect.
These findings suggest that L-selectin and IL-7R〈 play
key roles in the development of adaptive immune
responses to peanut antigen, while immune cell migra-
tion via CD34 or CD103-dependent mechanisms are not
required. When considering effective points of inter-
vention in PIA, our findings suggest minimal benefit in
targeting late-phase immune cell migration.Materials and methods
Mice
C57BL/6, CD103 (Cd103−/−) and IL-7 receptor (IL7R−/−)
deficient mice were purchased from The Jackson La-
boratory. IL7R−/− mice were backcrossed onto a Ly5.1
background. L-selectin deficient (L-sel−/−) [22] mice
were provided by Dr. H.J. Ziltener and CD34 deficient
(Cd34−/−) mice [23] were provided by Dr. T.W. Mak. All
animals were housed and bred in specific pathogen-free
conditions at The BRC. For all experiments, eight to ten
week old sex-matched mice were used and the Commit-
tee on Animal Care at UBC approved all procedures,
in accordance with the requirements of the Canadian
Council on Animal Care.
Peanut-induced anaphylaxis (PIA)
PIA was induced as previously described [5]. Briefly,
mice were sensitized by oral gavage with 1 mg peanut
protein (Kraft Naturals peanut butter) and 10 μg cholera
toxin (List Biological Laboratories) in 100μL sterile
dH2O, weekly for 4 weeks. Control mice received PBS
alone. Two weeks after the final sensitization, mice were
challenged by intraperitoneal injection of 5 mg crude
de-fatted peanut extract (CPE; Greer Laboratories) in
500μL PBS.
Clinical scoring
Symptoms were evaluated using the scoring system
described previously [5]. Animals were housed indivi-
dually and observed for temperature decreases and
development of clinical symptoms for 40 minutes post-
challenge. Rectal temperatures were measured using a
traceable expanded range digital thermometer (VWR) at
10-minute intervals. Clinical scores were assigned from
0–5, where 0 = no symptoms, 1 = repetitive scratching
of the ear canals, 2 = decreased activity or puffiness of
the eyes, 3 = periods of motionlessness for >1 minute,
4 = no response to whisker stimuli/prodding and 5 =
early endpoint triggered by seizures or convulsion.
Blood analysis (Histamine, Total IgE and IgE-mediated
CPE binding)
Blood was collected via cardiac puncture from anaesthe-
tized animals and diluted in 50ul PBS containing 2.5U
of heparin. Plasma was separated by centrifugation
and stored at -20C. Histamine levels were determined
using an enzyme immunoassay kit (Beckman Coulter /
Immunotech). Total IgE was assessed by ELISA using a
murine total IgE kit (BD Pharmingen, San Diego CA).
IgE-mediated CPE binding was assessed using a sand-
wich ELISA, similar to the protocol previously described
[5]. Briefly, plates were coated with anti-mouse IgE Ab
(Southern Biotech) overnight. Diluted serum samples
were then incubated overnight, coated with biotinylated
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ase (Invitrogen) and developed with a commercial ELISA
amplification system (Invitrogen). Resulting optical
densities were adjusted to a standard curve of biotiny-
lated CPE.
Passive systemic anaphylaxis (PSA)
PSA was performed as previously described [24]. For
histamine assessment, mice were sensitized by intraven-
ous injection of 2 μg of anti-DNP IgE (Sigma-Aldrich) in
200 μl HBSS. For body temperature assessments, mice
were sensitized with 60 μg of anti-DNP IgE (in-house,
clone SPE-7) in 200 μl HBSS. Anaphylaxis was induced
the next day by intravenous injection of 0.5-1.0 mg
DNP-HSA in 200μL HBSS. Anaphylaxis severity was
assessed by measuring rectal temperatures at 5-minute
intervals for 60 minutes or assessment of serum hista-
mine levels 5 minutes post-injection.
Statistical analysis
P values were calculated using unpaired two-way Stu-
dent’s t test.
Results
Reduced PIA pathology in IL7R−/− and L-sel−/− mice, but
not Cd34−/− or Cd103−/− mice
Initially, we performed a survey of IL7R−/−, L-sel−/−,
Cd34−/− and Cd103−/− mice to determine susceptibility
to PIA. As previously reported, naïve mice challenged
with CPE, regardless of genotype, did not exhibit any
significant changes in body temperature, clinical symp-
toms or histamine levels when compared to control
mice (Figure 1 and data not shown) [5]. To further
understand of B cell and T cells in PIA [5], we assessed
disease susceptibility in IL7R−/− mice, which exhibit
major defects in lymphoid development [9-11]. In wild-
type (Ly5.1) mice, antigen challenge resulted in rapid
decreases in body temperature (Figure 1A), observable
clinical symptoms (Figure 1B) and elevated serum his-
tamine (Figure 1C). In sharp contrast, IL7R−/− mice
were protected from disease, exhibiting limited or no
decrease in body temperature (Figure 1A), no clinical
symptoms (Figure 1B) and reduced histamine levels
(Figure 1C).
We next assessed PIA in L-sel−/− mice, as L-selectin is
required for homing and migration of naïve lymphocytes
and inflammatory immune cells in allergic models
[13,25-27]. As such, we hypothesized L-selectin plays a
role during either the sensitization stage or antigen chal-
lenge stage of disease. Following intraperitoneal chal-
lenge, L-sel−/− mice exhibited a minimal temperature
drop (Figure 1D), which recovered by the 40-minute
endpoint, and exhibited lower average clinical scores(Figure 1E), compared to wild type controls. However, at
the endpoint, L-sel−/− mice exhibited elevated levels
of serum histamine (Figure 1F) equivalent to wild
type controls.
CD34 plays a key role in mast cell migration and de-
velopment of allergic asthma [16,17], so we hypothesized
that Cd34−/− mice would also be protected from PIA.
However, following challenge, Cd34−/− mice exhibited
equivalent decreases in body temperature (Figure 2A),
clinical scores (Figure 2B) and serum histamine levels
(Figure 2C) to wildtype control mice.
CD103 is expressed on immune cells within the gut
mucosa and is a marker of DCs that maintain oral toler-
ance [21]. Following PIA induction, like Cd34−/− mice,
Cd103−/− mice exhibited wildtype decreases in body
temperature (Figure 2A), clinical symptoms (Figure 2B)
and serum histamine levels (Figure 2C). From this
initial screen, we determined that IL7R〈∀ and L-selectin
are critical for PIA, but neither CD34, nor CD103, play
major roles in the development of peanut-specific
immunity or resulting anaphylactic responses following
antigen exposure.
Wildtype levels of total and antigen-specific IgE in IL7R−/−
and L-sel−/− mice
As disease progression was impaired in IL7R−/− and
L-sel−/− mice, we also assessed total IgE production and
peanut-specific IgE binding in these animals. Surpris-
ingly, despite decreased disease severity and histamine
release, both IL7R−/− and L-sel−/− mice exhibited normal
or increased total plasma IgE levels, compared to wild-
type controls (Figure 3A,B) and normal levels of IgE-
mediated CPE binding (Figure 3C,D). Thus, reduced
disease severity in IL7R−/− and L-sel−/− mice is inde-
pendent of the ability to produce peanut-specific IgE
responses and may reflect lower affinity IgE production
or otherwise impaired immune responses.
L-sel−/− and IL7R−/− mice are fully susceptible to passive
system anaphylaxis (PSA)
L-selectin and IL7R〈∀-deficient animals exhibited
decreased susceptibility to PIA, which could result
from impaired immune sensitization or impaired ana-
phylactic responses. To test the latter possibility, we
assessed the susceptibility of L-sel−/− and IL7R−/− mice to a
PSA model. Mice were loaded with anti-DNP IgE and chal-
lenged with DNP-HSA. After challenge, both L-sel−/− and
IL7R−/− exhibited marked decreases in body temperature,
which recovered to initial body temperatures, similar
to their respective wildtype Bl/6 and Ly5.1 controls
(Figure 4A,D) and individual maximal temperature
decreases were indistinguishable across genotypes
(Figure 4B,E). Further, assessment of serum histamine levels



















































































Figure 1 IL-7Rα and L-selectin, are required for murine peanut-induced anaphylaxis. Mice were initially sensitized using peanut antigen
and cholera toxin via oral gavage for 4 consecutive weeks. Two weeks following the final sensitization, mice were challenged i.p. with crude
peanut extract. Body temperature (A, D) and average observed clinical scores (B, E) monitored every 10 minutes for 40 minutes post-injection.
Following the 40-minute endpoint, blood levels of histamine were assayed (C, F). Control mice were challenged with peanut immediately before
monitoring. (IL7R−/− and Ly5.1 n = 3, representative of 4 experiments; L-Sel−/− n = 8, Bl/6 n = 7, and control mice
n = 3, representative of 5 experiments; *represents p < 0.05; **represents p < 0.01; Error bars = SEM).
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mine release in all animals tested (Figure 4C,F). These find-
ings demonstrate that while L-sel−/− and IL7R〈∀ mice are
protected from PIA, both strains are capable of mounting a
robust systemic anaphylactic response when loaded with











































Figure 2 CD103 or CD34 are not required for murine peanut-induced
toxin via oral gavage for 4 consecutive weeks and were challenged i.p. wit
temperature decreases (A) and average clinical scores (B) monitored every
40-minute endpoint, blood levels of histamine were assayed (C). (Cd34−/− n
*represents p < 0.05; **represents p < 0.01; Error bars = SEM).Discussion
Peanut-induced anaphylaxis is a severe medical condi-
tion, with major effects on individual patient health and
social policy. Despite this, we lack a basic understanding
of unique underlying mechanisms of the disease. Recent
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10 minutes; observed for 40 minutes post-injection. Following the













































































Wild type L-Selectin -/- Wild type L-Selectin -/-
Wild type IL7R α -/-Wild type IL7R α -/-
A C
B D
Figure 3 Total and antigen-specific IgE in plasma of IL7R−/− and L-sel−/− mice. Following peanut sensitization and challenge, blood levels
of total IgE (A, B) and IgE-mediated CPE binding (C, D) were assayed at the 40 minute endpoint. (IL7R−/− n = 3 and Ly5.1 n = 4, representative of
3 experiments; L-Sel−/− n = 5 and Bl/6 n = 7, representative of 4 experiments; ***represents p < 0.001; Error bars = SEM).
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focussed on potential therapeutic interventions [5-7].
However, the importance of other specific immune
molecules and immune processes underlying this disease
are not well understood. In the current study, we used a
series of knockout mice to survey the importance of
cytokine receptors and adhesion/trafficking molecules in
susceptibility to food allergy with the goal of identifying
novel pathways as points of therapeutic intervention.
We were surprised to find that ablation of CD34 had
no effect on PIA, since this molecules has previously
been shown to play critical roles in a variety of immune
cell mediated disease models [16,18,28,29]. One possible
explanation is that after priming is complete, cell traf-
ficking no longer plays a role in the effector phase of
PIA due to the short timeline of disease (~1 hour).Although CD34 facilitates the migration of several
hematopoietic effector lineages (mast cells, eosinophils
and DCs) and Cd34−/− mice are protected in models of
asthma, ulcerative colitis and hypersensitivity pneumon-
itis, this likely reflects a delay, but not a block, in the
ability of CD34+ effector cells to migrate [16,18,28,29].
Thus, given sufficient time for priming, it is likely that
these mice “catch up” to their wildtype counterparts and
are equally susceptible to the acute phase of an anaphyl-
actic response.
CD103 is an E-cadherin ligand proposed to specify
tissue localization of CD103+ DCs and mucosal T cells
within the gut [30-34]. CD103+ DCs promote both Treg
development and Teff cell homing [30,32], and play a key
role in maintaining oral tolerance and gut homeostasis.















































































Figure 4 Equivalent passive systemic anaphylaxis induction in L-sel−/− and IL7R−/− mice. Mice were initially injected i.v. with anti-DNP
IgE to simulate sensitization. The next day, mice were injected i.v. with DNP-HSA to induce passive systemic anaphylaxis. Body temperature
measurements in L-sel−/− (A) and IL7R−/− (D) mice were taken at 5-minute intervals for 60 minutes post-injection. We identified maximal
individual temperature decreases (B, E) and assessed serum histamine levels (C, F) in animals sacrificed 5 minutes post-injection. (n = 4-5,
*represents p < 0.05; **represents p < 0.01; Error bars = SEM).
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essential role in Treg mediated functions in the gut.
Mullaly et al., demonstrated that CD103 was not
required for immune responses during helminth infec-
tion, and that mice which lack CD103 have normal
levels of Treg in the mesenteric lymphnodes or lamina
propria [35]. CD103 is also a marker of pro-regulatory
DCs, however very little work has focused on the func-
tional role of CD103 on these cells. Therefore we and
others [21], hypothesized that Cd103 ablation would
exacerbate disease, if pro-regulatory DCs modulate dis-
ease severity. Our findings demonstrate, however, that
loss of CD103 has no effect on PIA disease severity and,
thus, we propose that CD103 is a valuable marker of DC
and Treg subsets in the gut, but does not play an essential
role in the development or maintenance of oral tolerance.
Our findings demonstrate that disease severity is
reduced when adaptive immune responses are impaired.
This is particularly evident in IL7R−/− mice, whichexhibit severe defects in lymphoid development and sur-
vival, resulting in lymphopenia, low thymic cellularity
and impaired antibody production [9-11]. Surprisingly,
despite severe defects, IL7R−/− mice produce normal
serum Ig levels [36] and in the PIA model had wildtype
(or elevated) levels of both total IgE and antigen-specific
IgE. Nevertheless, IL7R−/− mice exhibited reduced circu-
lating histamine levels following peanut challenge. This
apparent discrepancy may reflect a severely limited anti-
body repertoire in IL7R−/− mice [37]. Without effective
IL-7R signalling, distal regions of the immunoglobulin
heavy chain loci become inaccessible, resulting in limited
B cell repertoires and, likely, lower affinity antibody pro-
duction [37]. In vivo, lower affinity antibodies likely
fail to induce a robust histamine release (despite normal
IgE levels), resulting in an absence of clinical symptoms
in the PIA model. This finding is consistent with the
known role of adaptive immunity in allergic responses,
and the importance of B cells reported in this model [5].
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in L-sel−/− mice, which exhibit an attenuated response.
L-selectin is involved in adaptive immunity both in naïve
T cell homing and the migration of mature Ag-specific
T cells during inflammation [12-14,26,27]. L-sel−/− mice
mount a normal antibody response [14], but are pro-
tected in a number of acute inflammatory and T-cell
mediated models of delayed-type hypersensitivity reaction
and experimental allergic encephalomyelitis [14,15,25-27].
Intriguingly, despite reduced disease pathology in L-sel−/−
mice, no difference in blood histamine or IgE levels
was observed following PIA-induction, suggesting that
they may represent an asymptomatic sensitization to
peanut allergen [38]. Our findings also suggest that
protection in L-sel−/− mice is via a histamine-
independent mechanism, (most likely regulating T cell
or neutrophil recruitment and migration). Intriguingly,
despite the reduced susceptibility to PIA, both IL7R−/−
and L-sel−/− mice exhibited normal susceptibility to
passive systemic anaphylaxis.
In summary, we have shown that targeting L-selectin
or IL7R〈∀ function is sufficient to reduce PIA responses,
while loss of CD34 or CD103 has no effect on disease
severity. More broadly, these findings suggest that inter-
ventions targeting initial immune sensitization are more
likely to meet with therapeutic success, by suppressing
effective antigen-specific antibody production and inhi-
biting late-phase anaphylaxis/mast cell responses. Con-
versely, therapies inhibiting immune cell migration
following antigen challenge are unlikely to have signifi-
cant benefits, particularly considering the rapid kinetics
of peanut-induced anaphylaxis.Conflict of interest
No conflict of interest is declared by any authors of this manuscript.Authors’ contributions
SM and JB designed and performed all experiments and wrote the
manuscript. EDB coordinated reagent procurement and initiation of the
project, participated in experiment harvests and edited the manuscript. MJG,
MCT, and ZJ performed selected assays and edited the manuscript. JSM and
KMM supervised trainees, edited the manuscript, and provided reagents. All
authors read and approved the final manuscript.Acknowledgements
We are grateful to Takahide Murakami for genotyping, Hermann J. Ziltener
for providing IL7R−/− and Lsel−/− mice, Helen Merkens and Kimberley Allan
for technical support, and the BRC Animal Care Facility for animal handling.
This work was funded by grants from the Canadian Group on Food Allergy
Research (CanGoFar; Grant #07B1), the AllerGen Network NCE and the
Canadian Institutes of Health Research (CIHR; MOP-84545). SM was
supported through a CIHR and Heart and Stroke Foundation of Canada
Fellowship from the Centre for Blood Research (CBR), JB was supported by
the Multiple Sclerosis Society of Canada, EJD was supported through a
NSERC Postgraduate Scholarship and a UBC 4-Year Fellowship and MJG
holds a fellowship from the CIHR/Michael Smith Foundation for Health
Research (MSFHR) Transplantation Training Program. KMM is a MSFHR
Scholar (Senior) and CBR Member.Author details
1The Biomedical Research Centre, University of British Columbia, Vancouver,
BC, Canada. 2Department of Microbiology & Immunology, Dalhousie
University, Halifax, NS, Canada.
Received: 13 June 2012 Accepted: 14 August 2012
Published: 31 August 2012
References
1. Bock SA, Muñoz-Furlong A, Sampson HA: Further fatalities caused by
anaphylactic reactions to food, 2001–2006. J Allergy Clin Immunol 2007,
119:1016–1018.
2. Kagan RS, Joseph L, Dufresne C, Gray-Donald K, Turnbull E, Pierre YS,
Clarke AE: Prevalence of peanut allergy in primary-school children in
Montreal, Canada. J Allergy Clin Immunol 2003, 112:1223–1228.
3. Sicherer SH, Muñoz-Furlong A, Sampson HA: Prevalence of peanut and
tree nut allergy in the United States determined by means of a random
digit dial telephone survey: a 5-year follow-up study. J Allergy Clin
Immunol 2003, 112:1203–1207.
4. Galli SJ, Tsai M, Piliponsky AM: The development of allergic inflammation.
Nature 2008, 454:445–454.
5. Sun J, Arias K, Alvarez D, Fattouh R, Walker T, Goncharova S, Kim B,
Waserman S, Reed J, Coyle AJ, Jordana M: Impact of CD40 Ligand, B Cells,
and mast cells in peanut-induced anaphylactic responses. J Immunol
2007, 179:6696–6703.
6. Arias K, Baig M, Colangelo M, Chu D, Walker T, Goncharova S, Coyle A,
Vadas P, Waserman S, Jordana M: Concurrent blockade of platelet-
activating factor and histamine prevents life-threatening peanut-induced
anaphylactic reactions. J Allergy Clin Immunol 2009, 124:307–314. e2.
7. Arias K, Chu DK, Flader K, Botelho F, Walker T, Arias N, Humbles AA,
Coyle AJ, Oettgen HC, Chang H-D, Van Rooijen N, Waserman S, Jordana M:
Distinct immune effector pathways contribute to the full expression of
peanut-induced anaphylactic reactions in mice. J Allergy Clin Immunol
2011, 127:1552–1561. e1.
8. Duarte J, Caridade M, Graca L: CD4-blockade can induce protection from
peanut-induced anaphylaxis. Front Immunol 2011, 2:1–9.
9. Peschon J, Morrissey P, Grabstein K, Ramsdell F, Maraskovsky E, Gliniak B:
Early lymphocyte expansion is severely impaired in interleukin 7
receptor-deficient mice. J Exp Med 1994, 180:1955–1960.
10. Maki K, Sunaga S, Komagata Y, Kodaira Y, Mabuchi A, Karasuyama H,
Yokomuro K, Miyazaki JI, Ikuta K: Interleukin 7 receptor-deficient mice lack
gammadelta T cells. PNAS 1996, 93:7172–7177.
11. Jacobs SR, Michalek RD, Rathmell JC: IL-7 Is essential for homeostatic
control of t cell metabolism in vivo. J Immunol 2010, 184:3461–3469.
12. Hickey MJ, Forster M, Mitchell D, Kaur J, De Caigny C, Kubes P: L-selectin
facilitates emigration and extravascular locomotion of leukocytes during
acute inflammatory responses in vivo. J Immunol 2000, 165:7164–7170.
13. Arbonés ML, Ord DC, Ley K, Ratech H, Maynard-Curry C, Otten G, Capon DJ,
Teddert TF: Lymphocyte homing and leukocyte rolling and migration are
impaired in L-selectin-deficient mice. Immunity 1994, 1:247–260.
14. Catalina MD, Carroll MC, Arizpe H, Takashima A, Estess P, Siegelman MH:
The route of antigen entry determines the requirement for l-selectin
during immune responses. J Exp Med 1996, 184:2341–2352.
15. Grewal IS, Foellmer HG, Grewal KD, Wang H, Lee WP, Tumas D, Janeway CA
Jr, Flavell RA: CD62L is required on effector cells for local interactions in
the CNS to cause myelin damage in experimental allergic
encephalomyelitis. Immunity 2001, 14:291–302.
16. Blanchet MR, Maltby S, Haddon DJ, Merkens H, Zbytnuik L, McNagny KM:
CD34 facilitates the development of allergic asthma. Blood 2007,
110:2005–2012.
17. Drew E, Merzaban JS, Seo W, Ziltener HJ, McNagny KM: CD34 and CD43
inhibit mast cell adhesion and are required for optimal mast cell
reconstitution. Immunity 2005, 22:43–57.
18. Blanchet M-R, Bennett JL, Gold MJ, Levantini E, Tenen DG, Girard M,
Cormier Y, McNagny KM: CD34 is required for dendritic cell trafficking
and pathology in murine hypersensitivity pneumonitis. Am J Respir Crit
Care Med 2011, 184:687–698.
19. Maltby S, Freeman S, Gold MJ, Baker JHE, Minchinton AI, Gold MR,
Roskelley CD, McNagny KM: Opposing roles for CD34 in B16 melanoma
tumor growth alter early stage vasculature and late stage immune cell
infiltration. PLoS One 2011, 6:e18160.
Maltby et al. Allergy, Asthma & Clinical Immunology 2012, 8:15 Page 8 of 8
http://www.aacijournal.com/content/8/1/1520. Blanchet M-R, Gold M, Maltby S, Bennett J, Petri B, Kubes P, Lee DM,
McNagny KM: Loss of CD34 leads to exacerbated autoimmune
arthritis through increased vascular permeability. J Immunol 2010,
184:1292–1299.
21. Scott CL, Aumeunier AM, Mowat AM: Intestinal CD103+ dendritic cells:
master regulators of tolerance? Trends Immunol 2011, 32:412–419.
22. Borsig L, Wong R, Hynes RO, Varki NM, Varki A: Synergistic effects of L- and
P-selectin in facilitating tumor metastasis can involve non-mucin ligands
and implicate leukocytes as enhancers of metastasis. PNAS 2002,
99:2193–2198.
23. Suzuki A, Andrew D, Gonzalo J, Fukumoto M, Spellberg J, Hashiyama M,
Takimoto H, Gerwin N, Webb I, Molineux G, Amakawa R, Tada Y,
Wakeham A, Brown J, McNiece I, Ley K, Butcher E, Suda T, Gutierrez-Ramos J,
Mak T: CD34-deficient mice have reduced eosinophil accumulation after
allergen exposure and show a novel crossreactive 90-kD protein. Blood
1996, 87:3550–3562.
24. Ujike A, Ishikawa Y, Ono M, Yuasa T, Yoshino T, Fukumoto M, Ravetch JV,
Takai T: Modulation of Immunoglobulin (Ig)E-Mediated Systemic
Anaphylaxis by Low-Affinity Fc Receptors for IgG. J Exp Med 1999,
189:1573–1579.
25. Szántó S, Gál I, Gonda A, Glant TT, Mikecz K: Expression of L-Selectin, but
Not CD44, is required for early neutrophil extravasation in antigen-
induced arthritis. J Immunol 2004, 172:6723–6734.
26. Tedder TF, Steeber DA, Pizcueta P: L-selectin-deficient mice have
impaired leukocyte recruitment into inflammatory sites. J Exp Med 1995,
181:2259–2264.
27. Steeber DA, Tang MLK, Green NE, Zhang X-Q, Sloane JE, Tedder TF:
leukocyte entry into sites of inflammation requires overlapping
interactions between the L-Selectin and ICAM-1 pathways. J Immunol
1999, 163:2176–2186.
28. Maltby S, Wohlfarth C, Gold M, Zbytnuik L, Hughes MR, McNagny KM: CD34
is required for infiltration of eosinophils into the colon and pathology
associated with DSS-induced ulcerative colitis. Am J Pathol 2010,
177:1244–1254.
29. Drew E, Huettner CS, Tenen DG, McNagny KM: CD34 expression by mast
cells: of mice and men. Blood 2005, 106:1885–1887.
30. Johansson-Lindbom B, Svensson M, Pabst O, Palmqvist C, Marquez G,
Förster R, Agace WW: Functional specialization of gut CD103+ dendritic
cells in the regulation of tissue-selective T cell homing. J Exp Med 2005,
202:1063–1073.
31. Jaensson E, Uronen-Hansson H, Pabst O, Eksteen B, Tian J, Coombes JL,
Berg P-L, Davidsson T, Powrie F, Johansson-Lindbom B, Agace WW: Small
intestinal CD103+ dendritic cells display unique functional properties
that are conserved between mice and humans. J Exp Med 2008,
205:2139–2149.
32. Sun C-M, Hall JA, Blank RB, Bouladoux N, Oukka M, Mora JR, Belkaid Y: Small
intestine lamina propria dendritic cells promote de novo generation of
foxp3 t reg cells via retinoic acid. J Exp Med 2007, 204:1775–1785.
33. Cepek KL, Shaw SK, Parker CM, Russell GJ, Morrow JS, Rimm DL, Brenner MB:
Adhesion between epithelial cells and T lymphocytes mediated by
E-cadherin and the |[alpha]|E|[beta]|7 integrin. Nature 1994, 372:190–193.
34. Karecla PI, Bowden SJ, Green SJ, Kilshaw PJ: Recognition of E-cadherin on
epithelial cells by the mucosal T cell integrin αM290β7 (αEβ7). European
Journal of Immunology 1995, 25:852–856.
35. Mullaly SC, Burrows K, Antignano F, Zaph C: Assessing the role of CD103
in immunity to an intestinal helminth parasite. PLoS ONE 2011, 6:e19580.
36. Erlandsson L, Licence S, Gaspal F, Lane P, Corcoran AE, Mårtensson I-L: Both
the pre-BCR and the IL-7Rα are essential for expansion at the pre-BII cell
stage in vivo. European Journal of Immunology 2005, 35:1969–1976.
37. Corcoran AE, Riddell A, Krooshoop D, Venkitaraman AR: Impaired
immunoglobulin gene rearrangement in mice lacking the IL-7 receptor.
Nature 1998, 391:904–907.
38. Assing K, Bodtger U, Poulsen LK: Seasonal dynamics of chemokine
receptors and CD62L in subjects with asymptomatic skin sensitization
to birch and grass pollen. Allergy 2006, 61:759–768.
doi:10.1186/1710-1492-8-15
Cite this article as: Maltby et al.: IL-7Rα and L-selectin, but not CD103 or
CD34, are required for murine peanut-induced anaphylaxis. Allergy,
Asthma & Clinical Immunology 2012 8:15.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
